Drug Profile
S 64315
Alternative Names: MIK-665; S-64315Latest Information Update: 03 Aug 2023
Price :
$50
*
At a glance
- Originator Servier; Vernalis
- Developer ADIR; IRIS; Novartis; Servier; Vernalis
- Class Antineoplastics; Small molecules
- Mechanism of Action MCL1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Acute myeloid leukaemia; Breast cancer
- Phase I Multiple myeloma; Non-Hodgkin's lymphoma
- No development reported Lymphoma; Myelodysplastic syndromes
Most Recent Events
- 31 May 2023 Institut de Recherches Internationales Servier in collabration with ADIR, a servier group company completes a phase I trial in Acute myeloid leukaemia (Combination therapy) in the US, Australia and France (NCT03672695)
- 06 Dec 2022 Institut de Recherches Internationales Servier and ADIR terminate a Acute myeloid leukaemia (Combination therapy, First-line therapy, In adults, In the elderly) in France (IV) (EudraCT2019-004896-38) (NCT04629443)
- 28 Jul 2022 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Combination therapy) in Australia (IV, Infusion)